KRAS and colorectal carcinoma: In the present study, we discovered that SLC25A21 expression was downregulated in KRAS-mutant CRC and that SLC25A21 downregulation was closely correlated with poor survival of KRAS-mutant CRC patients and selectively accelerated the cell growth, invasion, migration, and metastasis of CRC cells with KRAS mutation in vitro and in vivo.